{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:41:02Z","timestamp":1763037662203,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["Inter-agency agreement"],"award-info":[{"award-number":["Inter-agency agreement"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11606-021-07155-z","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T20:29:18Z","timestamp":1633120158000},"page":"3802-3809","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7469-4047","authenticated-orcid":false,"given":"David J.","family":"Graham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector S.","family":"Izurieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella G.","family":"Muthuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander T.","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueqin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efe","family":"Eworuke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charu","family":"Gandotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armen","family":"Avagyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wernecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Kelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Forshee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"MaCurdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"issue":"2","key":"7155_CR1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8.","journal-title":"Cell"},{"issue":"7","key":"7155_CR2","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jamacardio.2020.1282","volume":"5","author":"C Bavishi","year":"2020","unstructured":"Bavishi C, Maddox TM, Messerli FH. Coronavirus disease 2019 (Covid-19) infection and the renin angiotensin system blockers. JAMA Cardiol. 2020;5(7):745-747.","journal-title":"JAMA Cardiol."},{"key":"7155_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1155\/2012\/256294","volume":"2012","author":"C Tikellis","year":"2012","unstructured":"Tikellis C, Thomas MC. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept. 2012;2012:256-294.","journal-title":"Int J Pept."},{"issue":"17","key":"7155_CR4","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganthan","year":"2020","unstructured":"Vaduganthan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653-1659.","journal-title":"N Engl J Med."},{"key":"7155_CR5","first-page":"1","volume":"347","author":"CM Hales","year":"2019","unstructured":"Hales CM, Servais J, Martin CB, Kohen D. Prescription drug use among adults aged 40-79 in the United States and Canada. NCHS Data Brief. 2019;347:1-8.","journal-title":"NCHS Data Brief."},{"key":"7155_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.7326\/M20-1515","volume":"173","author":"K Mackey","year":"2020","unstructured":"Mackey K, King VJ, Gurley S, et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults. A living systematic review. Ann Intern Med. 2020;173:195-201.","journal-title":"Ann Intern Med."},{"issue":"25","key":"7155_CR7","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","volume":"382","author":"HR Reynolds","year":"2020","unstructured":"Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;382(25):2441-2448.","journal-title":"N Engl J Med."},{"key":"7155_CR8","doi-asserted-by":"publisher","unstructured":"Mehta N, Kalra A, Nowacki AS, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; https:\/\/doi.org\/10.1001\/jamacardio.2020.1855.","DOI":"10.1001\/jamacardio.2020.1855"},{"issue":"16","key":"7155_CR9","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1093\/cid\/ciaa624","volume":"71","author":"SY Jung","year":"2020","unstructured":"Jung SY, Choi JC, You SH, Kim WY. Association of renin-angiotensin-aldosterone system inhibitors with coronavirus disease 2019 (COVID-19)-related outcomes in Korea: a nationwide population-based cohort study. Clin Infect Dis. 2020;71(16):2121-2128.","journal-title":"Clin Infect Dis."},{"issue":"2","key":"7155_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jama.2020.11301","volume":"324","author":"EL Fosb\u00f8l","year":"2020","unstructured":"Fosb\u00f8l EL, Butt JH, \u00d8stergaard L, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA. 2020;324(2):168-177.","journal-title":"JAMA."},{"issue":"19","key":"7155_CR11","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1136\/heartjnl-2020-317393","volume":"106","author":"J Hippisley-Cox","year":"2020","unstructured":"Hippisley-Cox J, Young D, Coupland C et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020;106(19):1503-1511.","journal-title":"Heart."},{"issue":"5","key":"7155_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jtm\/taaa069","volume":"27","author":"G Chodick","year":"2020","unstructured":"Chodick G, Nutman A, Yiekutiel N, Shalev V. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with increased risk of SARS-CoV-2 infection. J Trav Med. 2020;27(5):1-3. doi: https:\/\/doi.org\/10.1093\/jtm\/taaa069.","journal-title":"J Trav Med."},{"key":"7155_CR13","doi-asserted-by":"publisher","unstructured":"Dublin S, Walker R, Floyd JS, et al. Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study. Am J Hypertens. 2020; doi: https:\/\/doi.org\/10.1093\/ajh\/hpaa168","DOI":"10.1093\/ajh\/hpaa168"},{"key":"7155_CR14","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","volume":"395","author":"FJ De Abajo","year":"2020","unstructured":"De Abajo FJ, Rodriguez-Mart\u00edn S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395:1705-1714.","journal-title":"Lancet."},{"key":"7155_CR15","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s40264-020-00994-5","volume":"43","author":"G Trifir\u00f2","year":"2020","unstructured":"Trifir\u00f2 G, Massari M, Da Cas R, et al. Renin-angiotensin-aldosteronesystem inhibitors and risk of death in patients hospitalized with COVID-19: a retrospective Italian cohort study of 43,000 patients. Drug Safety. 2020:43:1297-1308.","journal-title":"Drug Safety."},{"key":"7155_CR16","doi-asserted-by":"publisher","unstructured":"Khera R, Clark C, Lu Y, et al. Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with Coronavirus disease-19. J Am Heart Assoc. 2021; doi: https:\/\/doi.org\/10.1161\/JAHA.120.018086.","DOI":"10.1161\/JAHA.120.018086"},{"key":"7155_CR17","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.120.16314","volume":"77","author":"L Semenzato","year":"2021","unstructured":"Semenzato L, Botton J, Drouin J, et al. Antihypertensive drugs and COVID-19 risk: a cohort study of 2 million hypertensive patients. Hypertension. 2021;77:833-842.","journal-title":"Hypertension."},{"key":"7155_CR18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1532-5415.1999.tb01603.x","volume":"47","author":"BM Psaty","year":"1999","unstructured":"Psaty BM, Koepsell TD, Lin D, et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc. 1999;47:749-754.","journal-title":"J Am Geriatr Soc."},{"issue":"12","key":"7155_CR19","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1136\/oem.2004.014472","volume":"61","author":"DB Richardson","year":"2004","unstructured":"Richardson, D B. An incidence density sampling program for nested case-control analyses. Occup Environ Med. 2004;61(12):e59.","journal-title":"Occup Environ Med"},{"issue":"7","key":"7155_CR20","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/MLR.0000000000000729","volume":"55","author":"JB Segal","year":"2017","unstructured":"Segal JB, Chang HY, Du Y, Walston JD, Carlson MC, Varadhan R. Development of a claims-based frailty indicator anchored to a well-established frailty phenotype. Med Care. 2017;55(7):716-722.","journal-title":"Med Care."},{"issue":"6","key":"7155_CR21","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/aje\/kwx257","volume":"186","author":"JB Segal","year":"2017","unstructured":"Segal JB, Huang J, Roth DL, Varadhan R. External validation of the claims-based frailty index in the National Health and Aging Trends Study cohort. Am J Epidemiol. 2017;186(6):745-747.","journal-title":"Am J Epidemiol."},{"issue":"6","key":"7155_CR22","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.","journal-title":"J Clin Epidemiol."},{"issue":"11","key":"7155_CR23","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139.","journal-title":"Med Care."},{"issue":"1","key":"7155_CR24","first-page":"15","volume":"14","author":"BA Young","year":"2008","unstructured":"Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14(1):15-23.","journal-title":"Am J Manag Care."},{"issue":"11","key":"7155_CR25","first-page":"721","volume":"18","author":"HY Chang","year":"2012","unstructured":"Chang HY, WeinerJP, Richards TM, Bleigh SN, Segal JB. Validating the adapted diabetes complications severity index in claims data. Am J Manag Care. 2012;18(11):721-726.","journal-title":"Am J Manag Care."},{"issue":"25","key":"7155_CR26","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","volume":"382","author":"G Mancia","year":"2020","unstructured":"Mancia G, ReaF, Ludergnani M, Apolone G, Corrao G. Renin-algiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382(25):2431-2440.","journal-title":"N Engl J Med."},{"issue":"24","key":"7155_CR27","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1001\/jama.2020.20323","volume":"324","author":"SS Kadri","year":"2020","unstructured":"Kadri SS, Gundrum J, Warner S, et al. Uptake and accuracy of the diagnosis code for COVID-19 among US hospitalizations. JAMA. 2020;324(24):2553-2554.","journal-title":"JAMA."},{"key":"7155_CR28","doi-asserted-by":"crossref","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083-3107.","DOI":"10.1002\/sim.3697"},{"key":"7155_CR29","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1002\/sim.2790","volume":"26","author":"B Mukherjee","year":"2007","unstructured":"Mukherjee B, Liu I, Sinha S. Analysis of matched case\u2013control data with multiple ordered disease states: possible choices and comparisons. Stat Med. 2007;26:3240-3257.","journal-title":"Stat Med."},{"key":"7155_CR30","unstructured":"KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Available at: https:\/\/kdigo.org\/wp-content\/uploads\/2016\/10\/KDIGO-2021-BP-GL.pdf. Accessed February 25, 2021."},{"issue":"6","key":"7155_CR31","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137-e161. doi: https:\/\/doi.org\/10.1161\/CIR.0000000000000509.","journal-title":"Circulation."},{"issue":"17","key":"7155_CR32","doi-asserted-by":"publisher","first-page":"e426","DOI":"10.1161\/CIR.0000000000000597","volume":"138","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138(17):e426-e483. doi: https:\/\/doi.org\/10.1161\/CIR.0000000000000597.","journal-title":"Circulation."},{"issue":"4","key":"7155_CR33","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268-274.","journal-title":"Ann Intern Med."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-021-07155-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-021-07155-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-021-07155-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T02:14:47Z","timestamp":1664590487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-021-07155-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7155"],"URL":"https:\/\/doi.org\/10.1007\/s11606-021-07155-z","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"type":"print","value":"0884-8734"},{"type":"electronic","value":"1525-1497"}],"subject":[],"published":{"date-parts":[[2021,10,1]]},"assertion":[{"value":"12 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they do not have a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The authors are employees or contractors of the FDA or the CMS; however, other officials at the FDA and the CMS had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the Funder\/Sponsor"}},{"value":"The views expressed are the authors\u2019 and not necessarily those of the Centers for Medicare & Medicaid Services, the Food and Drug Administration, or the Department of Health and Human Services.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}